Regen BioPharma, Inc.

OTCPK:RGBP Stock Report

Market Cap: US$2.9m

Regen BioPharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

David Koos

Chief executive officer

US$10.1k

Total compensation

CEO salary percentage100.0%
CEO tenure3.1yrs
CEO ownership0.01%
Management average tenureno data
Board average tenure8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Koos's remuneration changed compared to Regen BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$775k

Sep 30 2023US$10kUS$10k

US$1m

Jun 30 2023n/an/a

US$1m

Mar 31 2023n/an/a

US$68m

Dec 31 2022n/an/a

US$1m

Sep 30 2022n/an/a

US$2m

Jun 30 2022n/an/a

US$910k

Mar 31 2022n/an/a

-US$67m

Dec 31 2021n/an/a

-US$6m

Sep 30 2021US$1n/a

-US$7m

Jun 30 2021n/an/a

-US$4m

Mar 31 2021n/an/a

US$6m

Dec 31 2020n/an/a

US$2m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019n/an/a

-US$454k

Sep 30 2019US$54kUS$54k

-US$3m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$887k

Dec 31 2018n/an/a

-US$2m

Sep 30 2018US$180kUS$180k

-US$5m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017n/an/a

-US$8m

Sep 30 2017US$181kUS$175k

-US$6m

Compensation vs Market: David's total compensation ($USD10.05K) is below average for companies of similar size in the US market ($USD681.24K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Koos (62 yo)

3.1yrs

Tenure

US$10,050

Compensation

Dr. David Raymond Koos, Ph D., DBA., served as Chairman of the Board of Directors, Chief Executive Officer, President, Secretary and Treasurer at SYBLEU INC. Dr. Koos serves as Chairman, CEO, President, Se...

Board Members

NamePositionTenureCompensationOwnership
David Koos
Chairman3.1yrsUS$10.05k0.012%
$ 348.6
Amit Patel
Member of Scientific Advisory Board9.5yrsno datano data
Ravinder Reddy
Member of Scientific Advisory Board1.3yrsno datano data
Weiping Min
Member of Scientific Advisory Board11.9yrsno datano data
David Suhy
Member of Scientific Advisory Board10.6yrsno datano data
Santosh Kesari
Member of Scientific Advisory Board8.8yrsno datano data
Hinrich Gronemeyer
Member of Scientific Advisory Board8.8yrsno datano data
William Blaner
Member of Scientific Advisory Board8.8yrsno datano data
Rohit Duggal
Member of Scientific Advisory Board8.8yrsno datano data
Jonathan Baell
Member of Scientific Advisory Board8.7yrsno datano data
Stefano Bertuzzi
Member of Scientific Advisory Board8.5yrsno datano data
Mohammad Haris
Member of Scientific Advisory Board1.3yrsno datano data

8.8yrs

Average Tenure

Experienced Board: RGBP's board of directors are considered experienced (8.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.